Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men Article Swipe
Joel M. Palefsky
,
Anna R. Giuliano
,
Stephen E. Goldstone
,
Brady Dubin
,
Alfred J. Saah
,
Alain Luxembourg
,
Christine Velicer
,
Joseph E. Tota
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/cid/ciaf584
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/cid/ciaf584
Background Critical gaps exist in our understanding of the progression from anal human papillomavirus (HPV) infection to same-type HPV-associated anal disease in HIV-negative men who have sex with men (MSM). We conduced a post hoc analysis of a phase 3 randomized 4-valent HPV vaccine trial (NCT00090285) to assess the natural progression of anal HPV infections to associated anal lesions among MSM. Participants 602 HIV-negative MSM aged 16–27 years. Methods HIV-negative MSM aged 16–27 years enrolled in the placebo arm from 18 countries were included. We estimated distribution of 9-valent HPV (9vHPV) vaccine types in intra-anal lesions (anal condyloma and anal intraepithelial neoplasia [AIN] 1–3), proportions and rates of progression from incident-persistent (no associated anal disease at baseline) intra-anal HPV infections to a same-type HPV-associated anal lesion, and cumulative incidence over 30 months. Results Predominant 9vHPV types detected were HPV6 (55.7%) and HPV11 (25.3%) in MSM with anal condyloma/AIN1, and HPV6 (30.5%), HPV16 (22.0%), and HPV11 (15.3%) in those with pooled AIN2/3. Progression from incident-persistent intra-anal 9vHPV infection to anal disease was driven primarily by HPV6, HPV11, and HPV16/18 infections for MSM with anal condyloma/AIN1 (63.0%, 85.7%, and 16.3%, respectively) and AIN2/3 (25.9%, 14.3%, and 32.4%, respectively). Cumulative incidence of anal condyloma/AIN1 and AIN2/3 in MSM with incident-persistent infection were 43.1% and 34.4%, respectively. Conclusion A high proportion of unvaccinated HIV-negative MSM with a new intra-anal 9vHPV infection, developed same-type HPV-associated anal disease. These findings support HPV vaccination of young HIV-negative MSM to prevent anal HPV infection and associated anal disease.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/cid/ciaf584
- OA Status
- hybrid
- OpenAlex ID
- https://openalex.org/W4415723583
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4415723583Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/cid/ciaf584Digital Object Identifier
- Title
-
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With MenWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-10-28Full publication date if available
- Authors
-
Joel M. Palefsky, Anna R. Giuliano, Stephen E. Goldstone, Brady Dubin, Alfred J. Saah, Alain Luxembourg, Christine Velicer, Joseph E. TotaList of authors in order
- Landing page
-
https://doi.org/10.1093/cid/ciaf584Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1093/cid/ciaf584Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W4415723583 |
|---|---|
| doi | https://doi.org/10.1093/cid/ciaf584 |
| ids.doi | https://doi.org/10.1093/cid/ciaf584 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/41162330 |
| ids.openalex | https://openalex.org/W4415723583 |
| fwci | 0.0 |
| type | article |
| title | Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| is_xpac | False |
| apc_list.value | 4320 |
| apc_list.currency | USD |
| apc_list.value_usd | 4320 |
| apc_paid.value | 4320 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 4320 |
| language | en |
| locations[0].id | doi:10.1093/cid/ciaf584 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S72350973 |
| locations[0].source.issn | 1058-4838, 1537-6591 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1058-4838 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Clinical Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Clinical Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/cid/ciaf584 |
| locations[1].id | pmid:41162330 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/41162330 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5079764395 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5097-3818 |
| authorships[0].author.display_name | Joel M. Palefsky |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I180670191 |
| authorships[0].affiliations[0].raw_affiliation_string | University of California San Francisco, San Francisco, CA, USA |
| authorships[0].institutions[0].id | https://openalex.org/I180670191 |
| authorships[0].institutions[0].ror | https://ror.org/043mz5j54 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I180670191 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | University of California, San Francisco |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Joel M Palefsky |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | University of California San Francisco, San Francisco, CA, USA |
| authorships[1].author.id | https://openalex.org/A5079655559 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5440-8859 |
| authorships[1].author.display_name | Anna R. Giuliano |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I3019308854 |
| authorships[1].affiliations[0].raw_affiliation_string | Center for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center, Tampa, FL, USA |
| authorships[1].institutions[0].id | https://openalex.org/I3019308854 |
| authorships[1].institutions[0].ror | https://ror.org/01xf75524 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I3019308854 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Moffitt Cancer Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Anna R Giuliano |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Center for Immunization and Infection Research in Cancer (CIIRC), Moffitt Cancer Center, Tampa, FL, USA |
| authorships[2].author.id | https://openalex.org/A5002956877 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-7585-3508 |
| authorships[2].author.display_name | Stephen E. Goldstone |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[2].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[2].institutions[0].id | https://openalex.org/I98704320 |
| authorships[2].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Stephen E Goldstone |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[3].author.id | https://openalex.org/A5083082478 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Brady Dubin |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[3].affiliations[0].raw_affiliation_string | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[3].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[3].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Brady Dubin |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[4].author.id | https://openalex.org/A5033398725 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Alfred J. Saah |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[4].affiliations[0].raw_affiliation_string | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[4].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[4].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Alfred Saah |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[5].author.id | https://openalex.org/A5078019988 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Alain Luxembourg |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[5].affiliations[0].raw_affiliation_string | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[5].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[5].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Alain Luxembourg |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[6].author.id | https://openalex.org/A5053472935 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Christine Velicer |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[6].affiliations[0].raw_affiliation_string | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[6].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[6].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Christine Velicer |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[7].author.id | https://openalex.org/A5059545333 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-1941-7685 |
| authorships[7].author.display_name | Joseph E. Tota |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[7].affiliations[0].raw_affiliation_string | Merck & Co., Inc., Rahway, NJ, USA |
| authorships[7].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[7].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Joseph E Tota |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Merck & Co., Inc., Rahway, NJ, USA |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1093/cid/ciaf584 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-31T00:00:00 |
| display_name | Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic | |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/cid/ciaf584 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S72350973 |
| best_oa_location.source.issn | 1058-4838, 1537-6591 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1058-4838 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Clinical Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Clinical Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/cid/ciaf584 |
| primary_location.id | doi:10.1093/cid/ciaf584 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S72350973 |
| primary_location.source.issn | 1058-4838, 1537-6591 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1058-4838 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Clinical Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Clinical Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/cid/ciaf584 |
| publication_date | 2025-10-28 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.3 | 40 |
| abstract_inverted_index.A | 215 |
| abstract_inverted_index.a | 33, 38, 122, 223 |
| abstract_inverted_index.18 | 81 |
| abstract_inverted_index.30 | 131 |
| abstract_inverted_index.We | 31, 85 |
| abstract_inverted_index.at | 116 |
| abstract_inverted_index.by | 174 |
| abstract_inverted_index.in | 5, 22, 76, 94, 144, 157, 204 |
| abstract_inverted_index.of | 8, 37, 52, 88, 108, 199, 218, 238 |
| abstract_inverted_index.to | 17, 47, 56, 121, 168, 242 |
| abstract_inverted_index.(no | 112 |
| abstract_inverted_index.602 | 63 |
| abstract_inverted_index.HPV | 43, 54, 90, 119, 236, 245 |
| abstract_inverted_index.MSM | 65, 71, 145, 181, 205, 221, 241 |
| abstract_inverted_index.and | 99, 106, 127, 141, 149, 154, 177, 187, 190, 194, 202, 211, 247 |
| abstract_inverted_index.arm | 79 |
| abstract_inverted_index.for | 180 |
| abstract_inverted_index.hoc | 35 |
| abstract_inverted_index.men | 24, 29 |
| abstract_inverted_index.new | 224 |
| abstract_inverted_index.our | 6 |
| abstract_inverted_index.sex | 27 |
| abstract_inverted_index.the | 9, 49, 77 |
| abstract_inverted_index.was | 171 |
| abstract_inverted_index.who | 25 |
| abstract_inverted_index.HPV6 | 139, 150 |
| abstract_inverted_index.MSM. | 61 |
| abstract_inverted_index.aged | 66, 72 |
| abstract_inverted_index.anal | 12, 20, 53, 58, 100, 114, 125, 147, 169, 183, 200, 231, 244, 249 |
| abstract_inverted_index.from | 11, 80, 110, 163 |
| abstract_inverted_index.gaps | 3 |
| abstract_inverted_index.have | 26 |
| abstract_inverted_index.high | 216 |
| abstract_inverted_index.over | 130 |
| abstract_inverted_index.post | 34 |
| abstract_inverted_index.were | 83, 138, 209 |
| abstract_inverted_index.with | 28, 146, 159, 182, 206, 222 |
| abstract_inverted_index.(HPV) | 15 |
| abstract_inverted_index.(anal | 97 |
| abstract_inverted_index.43.1% | 210 |
| abstract_inverted_index.9vHPV | 135, 166, 226 |
| abstract_inverted_index.HPV11 | 142, 155 |
| abstract_inverted_index.HPV16 | 152 |
| abstract_inverted_index.HPV6, | 175 |
| abstract_inverted_index.These | 233 |
| abstract_inverted_index.[AIN] | 103 |
| abstract_inverted_index.among | 60 |
| abstract_inverted_index.exist | 4 |
| abstract_inverted_index.human | 13 |
| abstract_inverted_index.phase | 39 |
| abstract_inverted_index.rates | 107 |
| abstract_inverted_index.those | 158 |
| abstract_inverted_index.trial | 45 |
| abstract_inverted_index.types | 93, 136 |
| abstract_inverted_index.years | 74 |
| abstract_inverted_index.young | 239 |
| abstract_inverted_index.(MSM). | 30 |
| abstract_inverted_index.14.3%, | 193 |
| abstract_inverted_index.16.3%, | 188 |
| abstract_inverted_index.32.4%, | 195 |
| abstract_inverted_index.34.4%, | 212 |
| abstract_inverted_index.85.7%, | 186 |
| abstract_inverted_index.AIN2/3 | 191, 203 |
| abstract_inverted_index.HPV11, | 176 |
| abstract_inverted_index.assess | 48 |
| abstract_inverted_index.driven | 172 |
| abstract_inverted_index.pooled | 160 |
| abstract_inverted_index.years. | 68 |
| abstract_inverted_index.(15.3%) | 156 |
| abstract_inverted_index.(25.3%) | 143 |
| abstract_inverted_index.(25.9%, | 192 |
| abstract_inverted_index.(55.7%) | 140 |
| abstract_inverted_index.(63.0%, | 185 |
| abstract_inverted_index.(9vHPV) | 91 |
| abstract_inverted_index.16–27 | 67, 73 |
| abstract_inverted_index.1–3), | 104 |
| abstract_inverted_index.AIN2/3. | 161 |
| abstract_inverted_index.Methods | 69 |
| abstract_inverted_index.Results | 133 |
| abstract_inverted_index.disease | 21, 115, 170 |
| abstract_inverted_index.lesion, | 126 |
| abstract_inverted_index.lesions | 59, 96 |
| abstract_inverted_index.months. | 132 |
| abstract_inverted_index.natural | 50 |
| abstract_inverted_index.placebo | 78 |
| abstract_inverted_index.prevent | 243 |
| abstract_inverted_index.support | 235 |
| abstract_inverted_index.vaccine | 44, 92 |
| abstract_inverted_index.(22.0%), | 153 |
| abstract_inverted_index.(30.5%), | 151 |
| abstract_inverted_index.4-valent | 42 |
| abstract_inverted_index.9-valent | 89 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Critical | 2 |
| abstract_inverted_index.HPV16/18 | 178 |
| abstract_inverted_index.analysis | 36 |
| abstract_inverted_index.conduced | 32 |
| abstract_inverted_index.detected | 137 |
| abstract_inverted_index.disease. | 232, 250 |
| abstract_inverted_index.enrolled | 75 |
| abstract_inverted_index.findings | 234 |
| abstract_inverted_index.baseline) | 117 |
| abstract_inverted_index.condyloma | 98 |
| abstract_inverted_index.countries | 82 |
| abstract_inverted_index.developed | 228 |
| abstract_inverted_index.estimated | 86 |
| abstract_inverted_index.incidence | 129, 198 |
| abstract_inverted_index.included. | 84 |
| abstract_inverted_index.infection | 16, 167, 208, 246 |
| abstract_inverted_index.neoplasia | 102 |
| abstract_inverted_index.primarily | 173 |
| abstract_inverted_index.same-type | 18, 123, 229 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 214 |
| abstract_inverted_index.Cumulative | 197 |
| abstract_inverted_index.associated | 57, 113, 248 |
| abstract_inverted_index.cumulative | 128 |
| abstract_inverted_index.infection, | 227 |
| abstract_inverted_index.infections | 55, 120, 179 |
| abstract_inverted_index.intra-anal | 95, 118, 165, 225 |
| abstract_inverted_index.proportion | 217 |
| abstract_inverted_index.randomized | 41 |
| abstract_inverted_index.Predominant | 134 |
| abstract_inverted_index.Progression | 162 |
| abstract_inverted_index.progression | 10, 51, 109 |
| abstract_inverted_index.proportions | 105 |
| abstract_inverted_index.vaccination | 237 |
| abstract_inverted_index.HIV-negative | 23, 64, 70, 220, 240 |
| abstract_inverted_index.Participants | 62 |
| abstract_inverted_index.distribution | 87 |
| abstract_inverted_index.unvaccinated | 219 |
| abstract_inverted_index.(NCT00090285) | 46 |
| abstract_inverted_index.respectively) | 189 |
| abstract_inverted_index.respectively. | 213 |
| abstract_inverted_index.understanding | 7 |
| abstract_inverted_index.HPV-associated | 19, 124, 230 |
| abstract_inverted_index.condyloma/AIN1 | 184, 201 |
| abstract_inverted_index.papillomavirus | 14 |
| abstract_inverted_index.respectively). | 196 |
| abstract_inverted_index.condyloma/AIN1, | 148 |
| abstract_inverted_index.intraepithelial | 101 |
| abstract_inverted_index.incident-persistent | 111, 164, 207 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| citation_normalized_percentile |